Oncology

Biotech

Senti slams brakes on CAR-NK program to eke out remaining cash

Senti, seeing the end of its cash runway hove into view, has dropped its liver cancer candidate and narrowed its focus onto two CAR-NK programs.
Nick Paul Taylor Jan 27, 2023 9:40am

Celularity warns substantial slice of staff of possible layoffs

Jan 27, 2023 6:30am

Phase 2 attrition jumps amid scale-back in trial activity

Jan 18, 2023 6:42am

AbbVie pays Anima $42M to go after undruggable targets

Jan 10, 2023 9:15am

Belharra's wave catches Genentech in $130M launch

Jan 4, 2023 10:45am

Astellas posts 2nd phase 3 win in a month for oncology antibody

Dec 16, 2022 7:45am
More News

No surprises: FDA rejects Y-mAbs' rare pediatric cancer drug

Dec 2, 2022 5:43am

ImmunityBio, aiming to hire 300 in 30 months, lays off staff

Oct 10, 2022 8:52am

BMS, ConcertAI ally to promote oncology digital clinical trials

Oct 6, 2022 5:00am

Bayer parts with AI drug hunter Exscientia

Aug 18, 2022 10:00am